在经历了大幅上涨后，由人工智能(AI)引领的科技板块正朝着连续第三年涨幅超过20%的目标迈进。与 此同时，这促使投资者提出一个熟悉的问题：接下来会怎样? 科技股12月的分化表现可能是一个早期信号，表明领涨力量正在收窄，尤其是在估值过高的股票中，波 动性正在表面之下回归。如果不是周三盘后美光科技(MU.US)业绩及指引大幅超出预期带来的提振，科 技板块似乎将迎来连续第二个月的下跌。在这种环境下，重新关注防御性板块股票以平衡科技持股风险 的条件已经成熟。 传统防御性板块，如蓝筹医药股、受监管的公用事业和必需消费品股，仍然可以发挥作用。量化策略师 Steven Cress深入挖掘那些结合了持久现金流、必需服务和关键增长指标的量化"强力买入"评级股票， 同时还考虑了板块和行业，以及五个因子评分——估值、增长、盈利能力、动量和分析师预期修订，筛 选出了四只高质量的防御性股票。如果2026年科技板块降温且经济增长保持温和而非强劲，这些公司可 能成为当前值得买（300785）入的最佳防御性股票。 1. 布鲁克菲尔德基础设施(BIP.US)——公用事业板块 布鲁克菲尔德基础设施拥有并运营一个全球性的高质量基础设施资产组合，包 ...

当司美格鲁肽、替尔泊肽靠着 "减肥神药" 的光环席卷全球市场，靶点、剂型、疗效升级不断，另一群 糖尿病患者的困境似乎被掩盖在这场"技术狂欢"之下—— 1型糖尿病（T1D）患者，全球约915万人，每天必须与胰岛素注射笔、血糖监测仪为伴，稍有不慎就可 能因严重低血糖或高血糖并发症危及生命。 直到几个月前，Vertex在ADA年会上抛出的一组数据，将这一领域推到聚光灯下：其干细胞疗法 Zimislecel治疗1型糖尿病的1/2期临床中，83%（10/12）患者在注射一年后完全摆脱胰岛素依赖，且未 再发生致命性低血糖。 更关键的是，这款疗法无需依赖稀缺的捐献胰岛，而是通过干细胞体外分化生成胰岛，一旦 2026年顺 利申报上市，有可能彻底改写1型糖尿病的治疗格局。 尽管还有待最终临床数据的确认，以及Zimislecel与免疫抑制剂长期共同使用带来的安全性问题，但其 仍是对一个百年未破的治疗困局的正面冲击，让患者看到"功能性治愈"的曙光。 那么，这款被寄予厚望的疗法，真能掀翻1型糖尿病治疗的旧桌子吗？ 01 915万患者的临床困境 当我们谈及糖尿病，近几年的焦点几乎全被2型糖尿病的 "减肥神药" 占据。司美格鲁肽上市后迅 ...

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.Soon, it will be countdown time, noting one by one the last minutes of 2025. But today, we can start early, counting down the last 12 investment days until the new year. The stock market will be closed on Dec. 25 for Christmas Day and opens for partial sessions on Dec. 24 and Dec. 31. What should you do during this countdown? Consider possible stocks, companies with great long-term prospects, ...

Core Viewpoint - Healthcare stocks have underperformed compared to broader equities this year, but there are still attractive investment opportunities in the sector for long-term investors [1] Group 1: CRISPR Therapeutics - CRISPR Therapeutics is a gene-editing company with potential catalysts for stock price growth, particularly with its therapy Casgevy for sickle cell disease and beta-thalassemia [4] - The company has been enhancing third-party coverage and establishing treatment centers for Casgevy, which is expected to see significant growth next year [5] - CRISPR is also developing SRSD107, a potential anticoagulant with promising phase 1 results, and CTX112, which targets various cancers and autoimmune disorders, both of which could contribute to stock price increases [6][8] Group 2: Vertex Pharmaceuticals - Vertex Pharmaceuticals has faced challenges this year, primarily due to its reliance on its cystic fibrosis (CF) treatments, but these continue to generate steady revenue [10] - In Q3, Vertex reported an 11% year-over-year revenue increase to $3.08 billion and a 4.7% increase in net earnings per share to $4.20, indicating strong performance in its core area [11] - The company is advancing new therapies, including zimislecel for Type 1 diabetes and candidates targeting kidney diseases, with regulatory submissions planned for next year [13][14]

分组1 - Colette Kress, CFO of Nvidia, indicated that geopolitical issues and competition in China are impacting the company's data center revenue outlook, with no revenue from China assumed in Q4 [1][6] - Nvidia's inventory increased by 32% and supply commitments rose by 63% sequentially, positioning for demand outside of China [1] - The U.S. government will receive a 25% revenue cut from Nvidia's H200 AI chip sales to approved customers in China, as announced by President Trump [5] 分组2 - Michelle Chang of Zoom emphasized a shift towards an AI-first strategy, focusing on enhancing workplace collaboration and developing new AI products [2] - Zoom's free cash flow margin reached 50%, aided by one-time improvements, but sustained progress is uncertain [3] - Enterprise net dollar expansion remains at 98%, with a goal to exceed 100% in the future [3] 分组3 - Virgin Galactic reported only $400,000 in revenue but is transitioning to a scalable operating model, with operating expenses down to $67 million [7][8] - The company aims for approximately $450 million in annual revenue and $100 million in adjusted EBITDA from two ships flying 125 missions a year [8] - Engineering milestones, such as a new oxidizer tank, are expected to enhance operational efficiency and reduce downtime [8] 分组4 - Bark's CFO highlighted a shift towards higher-value customers and improved retention, with marketing costs decreasing due to lower acquisition costs [9][10] - The company plans to increase margins through sourcing changes and a price increase in 2026 [10] 分组5 - Warner Bros. Discovery's CFO noted a strategic shift away from costly NBA rights to a standalone sports streaming app, expecting significant financial benefits [11][12] - HBO Max is projected to generate over $1.3 billion in EBITDA this year, with a target of 150 million streaming subscribers by 2026 [12] 分组6 - Texas Roadhouse is preparing for approximately 7% commodity inflation in 2026, with labor inflation expected to be around 3% to 4% [13][14] - The company plans to invest approximately $400 million in capital expenditures in 2026, focusing on new units and franchise acquisitions [14][15] 分组7 - DoorDash's CFO indicated that 2026 will be a year of heavy reinvestment while still achieving modest margin expansion [16][17] - The acquisition of Deliveroo is performing well, contributing approximately $200 million to EBITDA, with growth exceeding expectations [18] 分组8 - Vertex Pharmaceuticals is prioritizing capital investment in innovation and expansion, particularly in its kidney portfolio [19][20] - The company is focused on building a durable pain franchise while managing operating expenses and external uncertainties [20]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Core Viewpoint - Vertex Pharmaceuticals has established itself as a leader in the treatment of cystic fibrosis (CF), generating significant revenue and profit, and is now exploring growth in other therapeutic areas [1][2][5]. Group 1: Financial Performance - Vertex's revenue increased by 11% to over $3 billion in the latest quarter, with a net income of $1.1 billion on a GAAP basis, and the company anticipates up to $12 billion in revenue for the full year [6]. - The stock has appreciated more than 40% over the past three years, although it has recently declined by 10% from its peak in April [2][3]. Group 2: Product Portfolio and Growth Drivers - The CF business is the primary growth driver for Vertex, with CFTR modulators developed to treat nearly 95% of CF patients [5][6]. - Vertex has received regulatory approval for a gene editing therapy for blood disorders and a non-opioid pain management drug, Journavx, which has seen over 300,000 prescriptions filled since its launch [2][9]. - The company projects that Casgevy, the blood disorders treatment, will generate over $100 million in revenue by 2025, with significant growth expected next year [8]. Group 3: Research and Development - Vertex is conducting clinical trials for a candidate that may address the remaining 5% of CF patients who are not currently treatable with existing therapies, and is also developing a next-generation CFTR corrector, VX-828 [10]. - The company has strong intellectual property protections for its innovations, which will last into the late part of the next decade [10][11]. Group 4: Market Position and Strategy - Vertex's manufacturing is primarily based in the U.S., reducing vulnerability to potential import tariffs [11]. - The company is viewed as a strong investment opportunity due to its dominance in the CF market and growth potential in other therapeutic areas, trading at 24 times forward earnings estimates [13].

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder... ...

Core Insights - Vertex Pharmaceuticals announced clinical data demonstrating the benefits of CASGEVY (exagamglogene autotemcel) for patients aged 5 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) [1][2] - The data includes the first clinical results for children aged 5-11 years and long-term outcomes for patients aged 12 years and older, to be presented at the American Society of Hematology (ASH) Annual Meeting [1][4] Company Overview - Vertex is a global biotechnology company focused on creating transformative medicines for serious diseases, including SCD and TDT [28][29] - The company has a robust pipeline of investigational therapies across various serious diseases, leveraging deep insights into human biology [28] Product Information - CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy that aims to increase fetal hemoglobin (HbF) levels in patients with SCD and TDT [8][14] - The therapy has shown potential to reduce or eliminate vaso-occlusive crises (VOCs) in SCD patients and the need for regular blood transfusions in TDT patients [8][14] Clinical Study Results - In the Phase 3 CLIMB-151 study for children with SCD, all patients with sufficient follow-up achieved the primary endpoint of being free from VOCs for at least 12 consecutive months [5] - In the Phase 3 CLIMB-141 study for children with TDT, all patients with sufficient follow-up achieved transfusion independence for at least 12 consecutive months while maintaining a hemoglobin level of at least 9 g/dL [5] - Long-term data for patients aged 12 years and older showed that 100% of SCD patients achieved VOC-free status for a mean duration of 35.3 months, while 98.2% of TDT patients achieved transfusion independence for a mean duration of 41.4 months [4] Regulatory and Future Plans - Vertex plans to initiate global regulatory filings for CASGEVY in the 5-11 age group in the first half of next year, having received a Commissioner's National Priority Voucher from the FDA to expedite the review process [12] - The company aims to extend studies to include younger children aged 2-4 years [10][12]

Core Insights - Vertex Pharmaceuticals has shown strong long-term investment potential, with a stock increase of 91% over the past five years, driven by steady revenue growth from its market-leading franchise [1][2]. Company Overview - Vertex is the global leader in cystic fibrosis (CF) drugs, having revolutionized treatment and generated significant revenue. The company has also expanded its research into other disease areas, achieving recent approvals for Casgevy and Journavx [2][4]. Market Position - Vertex's dominance in the CF market is supported by patents expected to maintain its leadership until the late 2030s. The company has developed CFTR modulators that can treat nearly 95% of CF patients, making its therapies life-changing for many [5][7]. Financial Performance - Vertex's CF portfolio contributed to an 11% revenue increase, exceeding $3 billion in the latest quarter. The company anticipates full-year revenue between $11.9 billion and $12 billion, indicating strong future growth potential [8][9]. Strategic Expansion - The company's expansion into various treatment areas is seen as a strategic move to create additional revenue streams and enhance its attractiveness to investors, positioning Vertex as a significant player in the biotech sector [4][9].